The U.S. FDA approved a new indication for Zerbaxa (Ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABD/VABP) in patients 18 years and older.
This approval addresses the threat of antimicrobial-resistant infections. According to the U.S. CDC and Prevention, HABP and VABP are the second most common type of hospital-acquired infection in the U.S particularly in patients in the ICU.
Zerbaxa was approved in 2014 to treat complicated intra-abdominal infections for complicated urinary tract infections.
Read the Full FDA Press Release Here